

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

The board of directors' report on events of material significance in accordance with Chap. 13 Sec. 6 and Chap. 14 Sec. 8 of the Swedish Companies Act (2005:551)

The board of directors of Ascelia Pharma AB intends to resolve on a rights issue of units subject to the approval of the general meeting. The company's board of directors hereby submits the following, as a report in accordance with Chap. 13 Sec. 6 and Chap. 14 Sec. 8 of the Swedish Companies Act.

Since the presentation of the annual report for the financial year 2023, no events of material significance for the company's financial position have occurred except as set out in company's published interim report for the period 1 January – 31 March 2024. The interim report is available at the company's website, www.ascelia.com.

Malmö on 10 July 2024

(Signature page follows)

The Board of Directors of Ascelia Pharma AB (publ)

Peter Benson

Lauren Barnes

Hans Maier

Helena Wennerström

Niels Mengel